Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lilly pays $50mm up front for rights to Hanmi's BTK inhibitor HM71224

Executive Summary

Eli Lilly & Co. paid $50mm up front for exclusive global rights (excluding China, Hong Kong, Taiwan, and Korea) to Hanmi Pharmaceutical Co. Ltd.’s Bruton’s kinase inhibitor HM71224 for autoimmune diseases.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies